Aims/hypothesis This study was designed to ascertain whether human enteroendocrine cells express bitter taste receptors, and whether activation of these receptors with bitter-tasting ligands induces secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Methods We used human enteroendocrine NCI-H716 cells, isolated duodenal segments from mice, and whole mice as our experimental systems for investigating stimuli and mechanisms underlying GLP-1-and PYYstimulated release. We measured hormone levels by ELISA and determined bitter taste receptor expression by real-time quantitative PCR. We adopted a pharmacological approach using inhibitors and enhancers of downstream signalling pathways known to be involved in bitter taste transduction in taste bud cells to investigate these pathways in NCI-H716 cells. Results Using a pharmacological approach, we identified signalling pathways triggered by the denatonium benzoate (DB)-activated bitter receptors. This involved activation of α-gustducin (Gαgust)-the specific G-protein subunit that is also present in taste bud cells-reduction of intracellular cAMP levels and enhancement of phospholipase C (PLC) activity, which ultimately led to increased intracellular calcium concentrations and hormone release. Gavage of DB, followed by gavage of glucose, to db/db mice stimulated GLP-1 and subsequent insulin secretion, leading to lower blood glucose levels. Conclusions/interpretation Our study demonstrates that activation of gut-expressed bitter taste receptors stimulates GLP-1 secretion in a PLC-dependent manner. In diabetic mice, DB (a ligand of bitter taste receptor cells), when given via gavage, lowers blood glucose levels in diabetic mice after oral glucose administration, through increased secretion of GLP-1.
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Introduction
There are five distinct tastes-bitter, sweet, umami, sour and salty-and distinguishing between them is critical for determining the nutritive and toxic qualities of ingested material [1, 2] . Taste receptors for bitter, sweet and umami are activated when a tastant interacts with specialised G-protein-coupled receptors on taste cells in the taste buds present in the tongue and oropharynx [3] . These G-protein-coupled taste receptors can be divided into two groups: the superfamily of bitter taste receptors (TAS2Rs), and sweet and umami taste receptors (TAS1Rs). There are approximately 25 known human TAS2Rs [4] and three TAS1Rs (R1, R2 and R3). Unlike bitter taste receptors, which function as monomers or homomultimers, sweet receptors function as heterodimers [5] . Although much work remains to elucidate the full pathways for bitter, sweet and umami modulation in taste cells, significant progress has been made in recent years. All of these receptors interact with the specific Gα subunit α-gustducin (Gαgust), which is critical to the transduction of taste components [6, 7] . In taste cells, coupling of Gαgust to activated bitter taste receptors stimulates phosphodiesterase (PDE), which subsequently decreases intracellular cAMP levels [1] . In addition, the released Gβ 3 and Gγ 13 subunits activate phospholipase (PLC) β2, causing the generation of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ), two important mediators of calcium release [8] . The release of calcium from internal stores, in turn, induces the opening of cation channels and calcium influx, thereby resulting in neurotransmitter release and regulation of gene expression [1, 6] .
Outside of the specialised taste cells within the taste buds, Gαgust as well as Gβ 3 and Gγ 13 are expressed in enteroendocrine L cells of the gastrointestinal tract [9] . Moreover, both TAS1Rs [10, 11] and TAS2Rs exist outside of taste buds, because they are present in rodent and human gut, and in the mouse and human STC-1 and NCI-H716 enteroendocrine cell lines [12] [13] [14] .
The L cells secrete glucogen-like peptide (GLP-1), GLP-2 and peptide YY (PYY) in response to the presence of glucose, oligopeptides and NEFA in the gut [11, 15, 16] . Using an electrophysiological approach, Gribble and coworkers have shown that glucose and certain amino acids can trigger both electrical activity and GLP-1 secretion from the GLUTag cell line [17] [18] [19] . In addition, activating TAS1Rs in rodent gut and NCI-H716 cells also resulted in GLP secretion [11] .
We have reported that bitter tastants stimulate GLP-1 secretion from human enteroendocrine NCI-H716 cells [20, 21] , accompanied by upregulation of PDE and IP 3 receptor mRNA expression [21] . Furthermore, bitter tastant-mediated GLP-1 secretion requires activation of Gαgust in the cells [20] . We therefore hypothesised that human enteroendocrine L cells would secrete GLP-1 and PYY in response to activation of these receptors. GLP-1 has been extensively studied because of its glucose-dependent insulinotropic properties, and exenatide, a potent agonist of GLP-1 receptors, is now a treatment for type 2 diabetes [22, 23] . Both GLP-1 and PYY also have other physiologically significant functions of relevance to obesity and type 2 diabetes: they slow gastric emptying [24] [25] [26] and act as satiety factors [27, 28] . To investigate whether activation of bitter taste receptors in L cells induces GLP-1 and PYY secretion, we examined NCI-H716 human enteroendocrine cells and found that they express bitter taste receptors, the receptors are coupled to Gαgust, and their activation elicits orchestrated hormone release.
We also hypothesised that the stimulation of GLP-1 secretion through activation of gut-expressed bitter taste receptors in vivo would decrease blood glucose levels through the insulinotropic effect of GLP-1. Therefore, we performed OGTT after oral administration of bitter agonist to db/db mice, and measured blood glucose and plasma GLP-1 and insulin levels in a time-dependent manner.
Methods
Culture of NCI-H716 cells and secretion studies NCI-H716 cells were maintained in suspension culture as described by the American Type Culture Collection (Manassas, VA, USA). Two days before the experiments, cells were seeded into 24-well culture plates precoated with Matrigel [9] . Denatonium benzoate (DB; 1, 2, 5 and 10 mmol/l), quinine (0.1, 0.2, 0.5, 1 and 2 mmol/l) and DMSO were purchased from SigmaAldrich (St Louis, MO, USA). Cells were incubated in 5% CO 2 for 1 h at 37°C with different test agents or with 1% DMSO as the vehicle. The culture medium was collected for the measurement of GLP-1 and PYY by ELISA and RIA (Linco Research, St Charles, MO, USA), respectively, and normalised to protein content [8, 11, 29] . GLP-1 and PYY ELISAs (EMD Millipore, Billerica, MA, USA) were performed as described in the manufacturer's guide. GLP-1 concentrations in each sample were measured with a Fluoroskan Ascent FL machine (Thermo Fisher Scientific, Vantaa, Finland). The lowest level of GLP-1 that can be detected by the assay is 2 pmol/l, and the lowest level for the PYY assay is 6.5 pg/ml. cAMP ELISA NCI-H716 cells were treated with forskolin (10 μmol/l) and SQ22536 (10 μmol/l) (both from SigmaAldrich), quinine (2 mmol/l) and vehicle for 15 min. DB was added to the cells, and medium collected thereafter in a time-dependent manner (1, 5, 10 and 15 min). The cells were lysed with 0.1 mol/l HCl, and intracellular cAMP was assayed by ELISA (Enzo Life Sciences, Farmingdale, NY, USA) according to the manufacturer's guide. The results were normalised to protein concentration.
Conventional PCR of NCI-H716 cells Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA), and conventional PCR was performed as previously described [11] . The primers used are listed in electronic supplementary material (ESM) Table 1 .
Real-time PCR of NCI-H716 cells Expression of bitter taste receptors in NCI-H716 cells was determined with real-time quantitative PCR as described in the manufacturer's guide (Life Technologies, Grand Island, NY, USA). The 2 −ΔΔC t value compared with the gene encoding Gαgust (GNAT3) was determined using StepOne software (Life Technologies). GAPDH was used as an endogenous control. The results are from three to five individual experiments performed in triplicate. Information on the primers used in real-time PCR is given in ESM Table 2 .
Small interfering (si)RNA preparation and NCI-H716 cell transfection The predesigned siRNA duplexes for knockdown of Gαgust (product name 1175215 duplex), TAS2R4 (1148389), TAS2R43 (1148345) and TAS2R46 (1148361) were purchased from Bioneer (Daejeon, South Korea). A scrambled negative control siRNA was also purchased from Bioneer. Transfection with siRNA duplexes was performed with Lipofectamine RNAiMAX reagent (Invitrogen) as previously described [11] .
Calcium imaging NCI-H716 cells were seeded on a clearbottom 96-well black plate (Corning, Tewksbury, MA, USA). After differentiation, the medium was replaced with PBS and the mixture was incubated for 30 min with fura-2 AM dye as described previously [5, 11] . After 30 min, the medium was replaced with fresh PBS with or without 2-aminoethoxydiphenyl borate (2APB; 20 μmol/l; SigmaAldrich) or gallein (10 μmol/l; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and incubated for a further 30 min. Levels of intracellular free Ca 2+ ([Ca   2+ ] i ) were observed with a Nikon Eclipse TS 100 fluorescence imaging system (Nikon, Melville, NY, USA), and quantified with InCyt Im2 software (University of Cincinnati, Cincinnati, OH, USA). The number of cells observed was 10-20 per well.
Immunoblotting Cells were lysed in immunoprecipitation buffer, and immunoblotting was performed as described previously [11] . Individual proteins were detected with primary antibodies against the phosphorylated form of extracellular signal-regulated kinase 1/2 (ERK 1/2) (1:1,000 dilution; Cell Signaling, Danvers, MA, USA) and total ERK (1:5,000 dilution; Santa Cruz Biotechnology), and visualised by enhanced chemiluminescence. Signals were quantified by densitometry coupled with ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA) and Scion Image (Scioncorp, Frederick, MD, USA).
Membrane preparation and labelling and immunoprecipitation of membrane-associated G-proteins Cell membranes were purified as described previously [11, 30] . Aliquots of purified membranes (70-100 g protein) were incubated for 10 min at 25°C with 185-370 GBq [ 32 P]GTP-azidoanilide (ALT, Lexington, KY, USA) in the absence or presence of different concentrations of DB. Specific Gα proteins were immunoprecipitated with antibodies against Gαgust (Santa Cruz Biotechnology) and Gα i1,2 (Affinity BioReagents, Golden, CO, USA).
Secretion of GLP-1 from intact duodenum in vivo The duodenum was physically isolated from the stomach and the intestinal tract by clamps placed at the gastroduodenal junction and within the duodenum ∼5 cm distal to the gastroduodenal junction. The duodenum was flushed with 20 ml Hanks' balanced salt solution (HBSS, calcium-and magnesium-free), and the proximal 5 cm of duodenum was dissected out and placed in culture medium. Tissues were incubated in 5% CO 2 for 1 h at 37°C, before the addition of various concentrations of DB (0, 5 and 10 mmol/l) directly into the lumen of the duodenum. Medium was collected after 1 h, and GLP-1 levels were assayed by ELISA (EMD Millipore).
Animals Eight-week-old male Lepr −/− (db/db) mice and C57BL/6 were purchased from Daehan Biolink (DBL, Eumseoung-gun, Chungcheongbuk-do, South Korea). All mice were acclimated for 1 week in a room with a light/dark cycle of 12 h at a temperature ranging from 21°C to 23°C and moderate humidity (55-60%). Food and water were provided ad libitum. All animal study protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Kyung Hee University.
OGTT Mice were fasted for 18 h before OGTT experiments. Each mouse group was orally administered saline or 1 mg/kg DB just before glucose gavage (5 g/kg). Blood glucose was measured from the tail vein using the Accu-Chek Performa system (Roche Diagnostics, Mannheim, Germany) at six time points: 0 (before glucose gavage), 10 (10 min after glucose gavage), 20, 40, 90 and 120 min.
Multiplex assay Mice were fasted for 18 h before experiments. Each mouse group was orally administered saline or 1 mg/kg DB just before glucose gavage (2 g/kg). The blood collected from tail veins was immediately transferred into EDTA-coated microcentrifuge tubes containing dipeptidyl peptidase IV inhibitor, and the plasma was carefully separated 
Results
We found that DB and quinine stimulation of NCI-H716 cells resulted in the appearance of GLP-1 in the medium in a concentration-dependent manner (Fig. 1a) . Using conventional PCR, we confirmed that NCI-H716 cells express GNAT3 mRNA [23] and then determined that these cells also express mRNAs for several bitter receptors (TAS2R3, TAS2R4 and TAS2R5) (Fig. 1b) . Because of the lack of suitable antibodies against TAS2R, the relative expression of TAS2R proteins could not be determined. We next determined total expression levels of the bitter taste receptor mRNAs using real-time quantitative PCR (Table 1) . mRNA expression levels of the 25 human bitter taste receptors were compared with the expression of GNAT3, the Gαgust-encoding gene, and expression levels for the TAS2Rs were normalised to the level of GAPDH mRNA expression.
We used the radioactive non-hydrolysable GTP analogue [ 32 P]GTP-azidoanilide to investigate the presence of functional coupling of bitter taste receptors and G-proteins after DB treatment in the cell membranes from NCI-H716 cells. In untreated control membranes, there was constitutive GTPazidoanilide incorporation into Gα i1,2 ( Fig. 2b ) without any effect on Gαgust (Fig. 2a) . Treatment with DB led to a dosedependent increase in Gαgust activation (Fig. 2a) , which was apparent with DB concentrations as low as 0.5 mmol/l. Under these conditions, Gα i1,2 activation was markedly decreased, with ∼90% inhibition at 10 mmol/l DB (Fig. 2b) . Taken together, our findings provide the first direct indication of the involvement of specific G-proteins, known to be involved in bitter taste sensing, in this cell line.
To obtain further direct evidence of the involvement of bitter taste receptors in the mediation of DB-induced GLP-1 secretion, we used siRNAs directed against TAS2R4, TASR43, TASR46 and GNAT3 to reduce their expression levels. Our results show a decrease in GLP-1 secretion levels (Fig. 2c) when TAS2R4, TAS2R43, TAS2R46 or GNAT3 mRNA expression was reduced (Fig. 2d) .
We then began to probe the downstream pathways by which activation of bitter taste receptors induces secretion of peptide hormones. We found that short-term incubation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC), mimicked the action of DB by increasing the secretion of both GLP-1 (Fig. 3a) and PYY (Fig. 3b) from NCI-H716 cells. Inhibition of PKC with bisindolylmaleimide I decreased DB-induced secretion of GLP-1 (Fig. 3c) , supporting the hypothesis of a role for PKC in hormone release. We next determined whether cAMP and PDE were involved in GLP-1 secretion. We found that 3-isobutyl-1-methylxanthine (IBMX), a ubiquitous PDE inhibitor, inhibited DB-mediated GLP-1 secretion (Fig. 3d) . To evaluate if DB-mediated secretion was PLC dependent, we assessed PLC's ability to modulate DB-induced secretion of GLP-1 in NCI-H716 cells. The GLP-1 response to DB was abrogated by PLC inhibition with U73122 in a concentrationdependent manner, while the inactive control, U73343, had no effect (Fig. 3e) . Stimulation of bitter taste receptors also appears to activate ERK1/2, a well-described downstream target of PLC [31] , because phospho-ERK levels were increased in response to increasing concentrations of DB (Fig. 3f) . However, we found that PLC-mediated GLP-1 secretion by DB was not dependent on ERK activation because pharmacological inhibition of the ERK1/2 pathway with PD98059 failed to attenuate DB-mediated secretion of GLP-1 (Fig. 3e) . Taken together, these results indicate that NCI-H716 cells respond to bitter taste stimulation by releasing GLP-1 and PYY through involvement of both PLC and PDE signalling cascades (Fig. 3c) .
We also looked for DB-induced increases in [Ca 2+ ] i in NCI-H716 cells, as would be expected with PLC activation. We used single cell imaging to monitor changes in the concentrations of [Ca 2+ ] i in NCI-H716 cells loaded with a Ca 2+ indicator dye. In the absence of extracellular calcium, DB treatment increased [Ca 2+ ] i dose-dependently (Fig. 4a) . Preincubation of the Gβγ inhibitor, gallein, or the IP 3 receptor antagonist, 2APB, suppressed DB-mediated [Ca 2+ ] i release from the intracellular calcium stores (Fig. 4b) . In addition, we found that DB time-dependently decreased intracellular cAMP levels (Fig. 4c) . Quinine, a known potent bitter receptor activator, also decreased intracellular cAMP levels, and, as expected, the adenylyl cyclase (AC) activator, forskolin, caused a highly significant increase in cAMP levels, while SQ22536, an AC inhibitor, did not influence basal cAMP levels. Figure 4d provides a summary of the molecular mechanisms operating in NCI-H716 cells that are involved in bitter taste-mediated GLP-1 secretion.
To find out if the findings from NCI-H716 cells have any direct bearing on L cells in situ, we examined GLP-1 secretion from isolated mouse duodena in response to DB. There was a 2.5-fold increase in GLP-1 release from isolated duodenal specimens into the bathing medium over non-stimulated levels after addition of 10 mmol/l DB (p<0.001) for 1 h (Fig. 5) .
Finally, we performed an in vivo study using db/db mice to examine the physiological implication of the activation of gutexpressed bitter taste receptor. Mice were gavaged with glucose (5 g/kg body weight) after the first gavage with 1 mg/kg DB. DB-treated db/db mice had lower blood glucose levels 20 and 40 min after glucose gavage than the saline-treated group, which translated into lower AUC for glucose for the 120 min period after oral glucose (Fig. 6a, b) . DB also increased plasma GLP-1 (Fig. 6c) , which was probably the immediate cause of the increased insulin levels seen in the DB-treated animals (Fig. 6d) .
Discussion
In this study, we confirm that NCI-H716 cells contain functional bitter taste receptors and that activation of these receptors by DB and quinine results in direct coupling to Gαgust and subsequent GLP-1 and PYY secretion. Although much work remains to be carried out, we have also illuminated part of the bitter signalling pathway that results in GLP-1 and PYY secretion by DB.
We previously reported that glucose stimulates GLP-1 secretion from NCI-H716 cells [11] . The presence of specific G-protein subunits and other elements implicated in sensing of and response to sweet sensations in L cells of the intestine [11] led us to investigate whether bitter taste elements are also present in NCI-H716 cells. Approximately 25 human TAS2R genes have been identified, and many have overlapping agonist spectra, indicating redundancy in the human bitter taste receptor pathways [32] . We found that DB induces GLP-1 and PYY secretion in a concentration-dependent manner, and that the specific DB-sensitive, bitter receptor, TAS2R4 [4, 33] , as well as other bitter receptors are expressed in NCI-H716 cells.
We also investigated the downstream signalling pathways known to be involved in bitter taste receptor activation. The secretion of GLP-1 and PYY was found to be PLC and PKC dependent and required an increase in [Ca 2+ ] i that resulted from activation of PLC. These results are in agreement with those obtained by Masuho et al [34] , who reported that bitter tastants elicited responses through PLC pathways in mousederived intestinal STC-1 cells.
Our work with DB shows that stimulation of bitter taste receptors also results in the phosphorylation and activation of ERK, presumably mediated by PKC. This finding is corroborated by our previous work in NCI-H716 cells, which demonstrated that ERK is also activated when sucralose and glucose activate sweet taste receptors [11, 35] . However, pharmacological inhibition of the ERK pathway failed to inhibit the GLP-1 secretion elicited by DB and it is therefore likely that the ERK pathway is involved in growth, and not secretion, in NCI-H716 cells.
That the L cells in the gut would sense and respond to not only the nutrient content of food but also other chemical contents makes sense from a physiological perspective. In addition to being insulinotropic, GLP-1 slows gastric emptying and inhibits gastric motility [26, 27, 36] . In fact, under normal postabsorptive conditions, these are thought to be its major effects [37] . Therefore, bitter compounds might also be expected to induce GLP-1 secretion in order to prevent them from reaching the absorptive surfaces of enterocytes of the small bowel. Delayed gastric emptying would also lead to distension and subsequent emesis of the offending compound, and a feeling of satiety coupled with distension would lessen input of more of the substance. Therefore, induced increase in GLP-1 by bitter tastants may have an important role in host defence through reduction of toxic food intake.
The other products of the L cell-GLP-2 and PYYalso have significant physiological effects. PYY is released postprandially and inhibits gastric, pancreatic and intestinal secretions [38, 39] , as well as gastrointestinal motility [24, 25] . Although the initial finding by Batterham et al [28] that PYY is a satiety factor has been difficult to replicate, PYY is nevertheless a putative satiety factor. Therefore, the secretion of PYY would also have beneficial effects on lessening intake of the toxic substance. Intriguingly, GLP-1 and PYY have been found to mediate conditioned taste aversion in mice [40, 41] , a function that was not easily intuited on the basis of these peptides being involved in the assimilation of food and the regulation of rates of gastric emptying and gut motility.
From a pharmacological perspective, the blood glucoselowering effect of DB, through stimulation of GLP-1 secretion, implies that gut-expressed bitter taste receptors are eminently worthy of study. Compounds that activate these receptors in gut, such as a pro-compound that would be activated on entering the stomach, and that do not elicit a bitter perception at the level of taste, may counteract the hedonic effect of food, and indeed might actually induce an aversive response to food intake and activate satiety mechanisms. Further work on humans in vivo is needed to uncover the significance of these findings.
